INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Nintedanib (Primary) ; Sildenafil
- Indications Idiopathic pulmonary fibrosis; Lung disorders
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2017 Planned End Date changed from 15 Mar 2018 to 19 Apr 2018.
- 17 Oct 2017 Planned End Date changed from 14 May 2018 to 15 Mar 2018.